Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Simpson (Stevenage, United Kingdom), A. Kang'Ombe (Stevenage, United Kingdom), M. Costa (Stevenage, United Kingdom), F. Wilson (Stevenage, United Kingdom), W. Fahy (Stevenage, United Kingdom), R. Marshall (Stevenage, United Kingdom), C. Maden (Stevenage, United Kingdom), C. Coello (London, United Kingdom), A. Saleem (London, United Kingdom), D. Fairman (Stevenage, United Kingdom), M. Vahdati-Bolouri (Stevenage, United Kingdom), T. Maher (London, United Kingdom). Using a selective avß6 PET ligand to optimise early phase IPF clinical trials. 2245

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 LAM clinical trials and the state-of-the-art Source: International Congress 2014 – Advances in care for patients with lymphangioleiomyomatosis (LAM) Year: 2014 The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Do marker states improve measurement properties of utility instruments: a randomized multi-center trial in patients with chronic respiratory disease Source: Eur Respir J 2004; 24: Suppl. 48, 295s Year: 2004 Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century" Year: 2014 The clear evidence for pulmonary rehabilitation in chronic lung disease - a review of the most important randomised controlled trials Source: International Congress 2018 – PG14 The evolving world of pulmonary rehabilitation Year: 2018 Absence of early metabolic response assessed by 18F-FDG PET-CT after initiation of antifibrotic drugs in IPF patients. Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Phase I-II clinical trials of gamma-Glu-Trp in patients with lung tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Preliminary data of prospective comparison of hybrid PET and dedicated PET in patients with pulmonary lesions Source: Eur Respir J 2002; 20: Suppl. 38, 601s Year: 2002 COPD treatment from pathophysiology to clinical trials Source: ERS Live 2007 Year: 2007 Evaluation of data requirements to establish biologic quality control ranges in a multi-center clinical trial for inhaled insulin Source: Annual Congress 2008 - New challenges and maintained quality: lung function for the future Year: 2008 New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014 COPD exacerbations in the phase 3 revefenacin clinical trial program Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Adalimumab treatment in patients with sarcoidosis: An open clinical trial using FDG-PET Source: Annual Congress 2010 - Sarcoidosis: from the bench to the bedside Year: 2010 Helium-hyperoxia a novel treatment for optimizing pulmonary rehabilitation: a randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 327s Year: 2007